US EditionPleoPharma Presents Promising Phase 2b Data on PP-01 for Cannabis Withdrawal
Summary by MyChesCo
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
PleoPharma Presents Promising Phase 2b Data on PP-01 for Cannabis Withdrawal
PHOENIXVILLE, PA — PleoPharma, Inc. shared encouraging findings from its Phase 2b clinical trial of PP-01, a novel treatment for Cannabis Withdrawal Syndrome (CWS), during the 2025 annual meeting of The College on Problems of Drug Dependence in New Orleans, Louisiana. The trial evaluated the safety and effectiveness of PP-01, a dual-mechanism, once-daily oral therapy, in participants with moderate to severe Cannabis Use Disorder (CUD). During th…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
